• Biovitrum AB, of Stockholm, Sweden, acquired the exclusive license and distribution rights to Aloxi (palonosetron hydrochloride) in Nordic territories from Helsinn Healthcare SA, of Lugano, Switzerland. The product, marketed in the U.S. by MGI Pharma Inc., of Minneapolis, is a long-lasting antiemetic belonging to the second generation of serotonin (5-HT3) antagonists, the leading class for the prevention of nausea and vomiting induced by chemotherapy. In the U.S., more than 3 million treatments have been completed. Aloxi is on the market in some European countries, as well as in several countries of Latin America under the trade name Onicit. Helsinn is Aloxi’s worldwide licensor. Financial terms were not disclosed.

• BioXell SpA, of Milan, Italy, and Lay Line Genomics SpA, of Rome, entered an exclusive worldwide agreement for the development and commercialization of MNAC13, a humanized monoclonal antibody, currently in preclinical development as a pain therapeutic. Terms were not disclosed, but Lay Line Genomics is receiving an up-front payment, development milestones and royalties on eventual product sales. MNAC13 blocks the action of the pain mediator nerve growth factor by binding to NGF receptor tyrosine kinase (TrkA).

• Evotec AG, of Hamburg, Germany, and Apeiron Biologics GmbH, of Vienna, Austria, signed a deal to develop small molecules targeting a concept for pain relief. During the initial phase of the collaboration, the companies jointly will develop tailored biochemical and cellular assays, and Evotec will aim to identify hit molecules. The companies then will focus on identifying a lead compound to take into preclinical development and through proof-of-concept studies.

• ExonHit Therapeutics SA, of Paris, will move to the continuous trading category of the Alternext market of the Euronext stock exchange in Paris, effective March 6. Euronext made the decision after a three-month observation period. ExonHit completed its IPO on Nov. 16, and since then its share price has risen by 66 percent to €4.80 from an issue price of €2.89.

• Genmab A/S, of Copenhagen, Denmark, acquired exclusive worldwide rights to angiogenesis targets identified by Adelaide, Australia-based Bionomics Ltd. to develop therapeutics for cancer and other diseases. Under the terms, Bionomics will receive an up-front fee, plus milestones and potential royalties.

• OxyPharma AB, of Stockholm, Sweden, received a patent grant from the Swedish Patent Office for its candidate drugs for rheumatoid arthritis and multiple sclerosis, Rob 803 and Rob 895, respectively. Rob 803 currently is undergoing a Phase I clinical trial, and a Phase IIa clinical trial is planned for September.

• ReNeuron Group plc, of Guildford, UK, said initial in vivo testing of its ReN004 candidate stem cell lines showed them to have attributes that might favor the reversal of the neurological deficits seen in Parkinson’s disease. The human cell lines were generated using ReNeuron’s patented c-mycERTAM stem cell expansion technology, and were pre-screened for both genetic stability and their ability to differentiate into tyrosine hydroxylase-expressing neurons. TH is a marker for a dopaminergic stem cell phenotype.

No Comments